Issue Date: September 9, 2013 | Web Date: September 5, 2013
Firms Spar Over Hepatitis Drug
As Gilead prepares for the launch of sofosbuvir, a small-molecule hepatitis C treatment that is expected to rake in billions of dollars annually, competitors are angling for a piece of the action. The latest firm to come forward is Merck & Co., which alleges that sofosbuvir’s structure is covered by patents generated in its search for hepatitis C treatments.
According to the Centers for Disease Control & Prevention, roughly 3.2 million Americans are . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society